{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:21:36Z","timestamp":1754396496663,"version":"3.37.3"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Science and Technology Commission","doi-asserted-by":"crossref","award":["csct2016shms-ztzx10004"],"award-info":[{"award-number":["csct2016shms-ztzx10004"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Commission of Chongqing, China PR.","award":["2018QNXM032"],"award-info":[{"award-number":["2018QNXM032"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81700158"],"award-info":[{"award-number":["81700158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Chronic myeloid leukemia (CML) is relatively rare in childhood and few studies have reported the clinical use of imatinib (IM) in pediatric CML. In this study, we evaluated the efficacy and tolerability of IM in children and adolescents with CML.<\/jats:p>\n            <jats:p>We investigated 21 patients under 18 years of age with newly diagnosed CML and treated with IM in Children's Hospital of Chongqing Medical University between May 2014 and February 2018. The disease was staged according to the European LeukemiaNet criteria and the IM dose was determined based on the disease stage. Cumulative responses and survival probabilities were estimated according to the Kaplan\u2013Meier method.<\/jats:p>\n            <jats:p>The estimated complete hematologic response rate of chronic phase-chronic myeloid leukemia (CML-CP) was 89.5% at 3 months. The complete cytogenetic response rates increased with time, reaching 47.4%, 73.7%, and 80.3% at 6, 12, and 24 months, respectively. The cumulative major molecular response rates were 42.1% and 76.3% at 12 and 24 months, respectively. With a median follow-up time of 33.8 months (range, 3.2\u201361.7 months), the estimated 2-year overall survival (OS) rate for CML was 95.2% (95% confidence interval [CI], 70.7%\u201399.3%). None of the CML-CP patients progressed to the accelerated phase or had a blast crisis. The 2-year OS and progression-free survival rates for the CML-CP cohort were both 100%, while the estimated 2-year event-free survival rate was 68% (95% CI, 42.1%\u201384.2%). None of the patients in this group had treatment-related deaths or IM discontinuation due to drug toxicities, and only 1 patient had a grade III\u2013IV nonhematologic adverse event. Overall, anemia was the most common adverse effect and 42.9% of patients had a decrease in bone mineral density.<\/jats:p>\n            <jats:p>IM was effective and the adverse effects were well-tolerated throughout the follow-up period in Chinese CML patients under 18 years of age.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019150","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:10:43Z","timestamp":1581538243000},"page":"e19150","source":"Crossref","is-referenced-by-count":11,"title":["Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia"],"prefix":"10.1097","volume":"99","author":[{"given":"Mengyue","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, P.R China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmin","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, P.R China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhao","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, P.R China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, P.R China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizhou","family":"An","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, P.R China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Children's Hospital of Chongqing Medical University"},{"name":"Chongqing Key Laboratory of Pediatrics, Chongqing, P.R China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,2]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"R2-20230915","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"e27422","DOI":"10.1002\/pbc.27422","article-title":"Temporal trends in the proportion of \u201ccure\u201d in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: a population-based study","volume":"65","author":"Drozdov","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1080\/10428194.2017.1422860","article-title":"The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China","volume":"59","author":"Shao","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s12098-015-2007-9","article-title":"Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia-chronic phase","volume":"83","author":"Ganta","year":"2016","journal-title":"Indian J Pediatr"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"De Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2009.021154","article-title":"Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group","volume":"95","author":"Cervantes","year":"2010","journal-title":"Haematologica"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1210\/jc.2012-2426","article-title":"Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects","volume":"98","author":"Vandyke","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:06:52Z","timestamp":1694819212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019150"}},"subtitle":["A single-center experience in China"],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019150","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}